Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
0.381 ^USD	+2.97%		-0.03%	-17.19%

15/05	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	MT
14/05	Transcript : Singular Genomics Systems, Inc., Q1 2024 Earnings Call, May 14, 2024

Singular Genomics Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

March 03, 2023 at 02:31 am IST

Singular Genomics Systems, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was USD 0.765 million. Net loss was USD 21.1 million compared to USD 19.76 million a year ago.

Basic loss per share from continuing operations was USD 0.29 compared to USD 0.27 a year ago.

Latest news about Singular Genomics Systems, Inc.

Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	15/05	MT
Transcript : Singular Genomics Systems, Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q1 Revenue $0.4M, vs. Street Est of $0.7M	15/05	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	20/03	MT
Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024	19/03
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q4 Revenue $1.1M, vs. Street Est of $1.04M	19/03	MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Singular Genomics Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03	CI
North American Morning Briefing : Investors -2-	18/03	DJ
Transcript : Singular Genomics Systems, Inc. - Special Call	05/02
Singular Genomics Systems, Inc. Showcases New G4X? Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform	05/02	CI
Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis	05/02	CI
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	22/01	MT
Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023	08/01	CI
Singular Genomics Systems Expects 31% Growth in Q4 Revenue	08/01	MT
Transcript : Singular Genomics Systems, Inc., Q3 2023 Earnings Call, Nov 14, 2023	15/11
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q3 Revenue $0.5M	15/11	MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Fluent BioSciences Inc. Announces A Partnership with Singular Genomics	02/11	CI
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	12/23/12	MT
Singular Genomics Systems, Inc.(NasdaqGS:OMIC) dropped from S&P Global BMI Index	18/23/18	CI
Transcript : Singular Genomics Systems, Inc. Presents at UBS MedTech, Tools and Genomics Summit 2023, Aug-16-2023 09:00 AM	16/23/16
UBS Adjusts Singular Genomics Systems Price Target to $0.90 From $1, Maintains Neutral Rating	10/23/10	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $1 From $1.15, Maintains Neutral Rating	10/23/10	MT
Transcript : Singular Genomics Systems, Inc., Q2 2023 Earnings Call, Aug 09, 2023	10/23/10

Chart Singular Genomics Systems, Inc.

Duration

Period

More charts

Company Profile

Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.

Sector

Biotechnology & Medical Research

Calendar

30/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Singular Genomics Systems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.381 USD

Average target price

0.75 USD

Spread / Average Target

+96.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SINGULAR GENOMICS SYSTEMS, INC.	-17.19%	28.23M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research